


Claims:

1. A compound selected from the group consisting of:

compounds of formula (I)



wherein

U is O or a lone pair,

V is a) O, S, NR¹, or CH₂, and L is lower-alkylene or lower-alkenylene,

b) -CH=CH- or -C≡C-, and L is lower-alkylene or a single bond,

W is CO, COO, CONR², CSO, CSNR², SO₂, or SO₂NR²,

X is hydrogen or one or more optional halogen and/or lower-alkyl substituents,

m is 2,

n is 0 to 7,

A¹ is hydrogen, lower-alkenyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy, or thio-lower-alkoxy,

A² is cycloalkyl, cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkinyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy or thio-lower-alkoxy,

A³ and A⁴ independently from each other are hydrogen or lower-alkyl, or

A¹ and A² or A¹ and A³ are bonded to each other to form a ring and -A¹-A²- or

-A¹-A³- are lower-alkylene or lower-alkenylene, optionally substituted by R³, in which one -CH₂- group of -A¹-A²- or -A¹-A³- can optionally be replaced by NR⁴, S, or O,

A⁵ is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkyl optionally substituted with hydroxy or lower-alkoxy, alkenyl optionally substituted with hydroxy, or alkadienyl optionally substituted with hydroxy,

R³ is hydroxy, lower-alkoxy, thio-lower-alkoxy, N(R⁵,R⁶), or lower-alkyl optionally substituted by hydroxy,

R^1 , R^2 , R^4 , R^5 , and R^6 independently from each other are hydrogen or lower-alkyl;


pharmaceutically acceptable salts of compounds of formula (I); and

pharmaceutically acceptable esters of compounds of formula (I).

2. The compound according to claim 1, wherein U is a lone pair.
3. The compound according to claim 2, wherein V is O or CH_2 , and L is lower-alkylene or lower-alkenylene.
4. The compound according to claim 2, wherein V is $-\text{C}\equiv\text{C}-$ and L is lower-alkylene or a single bond.
5. The compound according to claim 3, wherein n is 0.
6. The compound according to claim 3, wherein A^1 is lower-alkyl.
7. The compound according to claim 6, wherein A^1 is methyl or ethyl.
8. The compound according to claim 3, wherein A^2 is lower-alkenyl, or lower-alkyl optionally substituted by hydroxy or lower-alkoxy.
9. The compound according to claim 8, wherein A^2 is 2-propenyl or 2-hydroxy-ethyl.
10. The compound according to claim 3, wherein A^1 and A^2 are bonded to each other to form a ring and $-A^1-A^2-$ is lower-alkylene or lower-alkenylene, optionally substituted by R^3 , in which one $-\text{CH}_2-$ group of $-A^1-A^2-$ can optionally be replaced by NR^4 , S, or O, wherein R^3 and R^4 are as defined in claim 1.
11. The compound according to claim 3, wherein A^3 is hydrogen.

12. The compound according to claim 11, wherein A^4 is hydrogen.
13. The compound according to claim 3, wherein A^5 is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, or lower-alkyl optionally substituted with hydroxy or lower-alkoxy.
14. The compound according to claim 13, wherein A^5 is phenyl or benzyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine and chlorine, or wherein A^5 is lower-alkyl.
15. The compound according to claim 14, wherein A^5 is phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, butyl, or pentyl.
16. The compound according to claim 3, wherein W is COO, $CONR^2$, CSO, or $CSNR^2$, and R^2 is hydrogen.
17. The compound according to claim 3, wherein X is hydrogen.
18. The compound according to claim 3, wherein X is fluorine.
19. A compound selected from the group consisting of:

compounds of formula (VII)



wherein

- V is O or CH_2 ;
- L is lower-alkylene or lower-alkenylene;
- W is COO, CONH, CSNH or CSO;
- A^1 is hydrogen or lower-alkyl;


A² is lower alkyl or lower alkenyl;
m is 2; and
A⁵ is lower alkyl, phenyl or lower alkyl phenyl, wherein the phenyl group is optionally substituted with halogen;

pharmaceutically acceptable salts of compounds of formula (VII); and

pharmaceutically acceptable esters of compound of formula (VII).

20. The compound according to claim 19, wherein V is CH₂.
21. The compound according to claim 19, wherein V is O.
22. The compound according to claim 21, wherein W is COO.
23. The compound according to claim 21, wherein W is CONH.
24. The compound according to claim 23, wherein the compound of formula (VII) is 6-[4-(Allyl-methyl-amino)-but-2-enyloxy]-3,4-dihydro-2H-quinoline-1-carboxylic acid (4-fluoro-phenyl)-amide.
25. The compound according to claim 24, which is 6-[4-(Allyl-methyl-amino)-but-2-enyloxy]-3,4-dihydro-2H-quinoline-1-carboxylic acid (4-fluoro-phenyl)-amide.
26. The compound according to claim 21, wherein W is CSNH.
27. The compound according to claim 21, wherein W is CSO.
28. A process for the manufacture of a compound selected from the group consisting of:

compounds of formula (I)



wherein

U is O or a lone pair,

V is a) O, S, NR^1 , or CH_2 , and L is lower-alkylene or lower-alkenylene,

b) $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$, and L is lower-alkylene or a single bond,

W is CO, COO, CONR^2 , CSO, CSNR^2 , SO_2 , or SO_2NR^2 ,

X is hydrogen or one or more optional halogen and/or lower-alkyl substituents,

m is 1 or 2,

n is 0 to 7,

A^1 is hydrogen, lower-alkenyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy, or thio-lower-alkoxy,

A^2 is cycloalkyl, cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkinyl, or lower-alkyl optionally substituted by hydroxy, lower-alkoxy or thio-lower-alkoxy,

A^3 and A^4 independently from each other are hydrogen or lower-alkyl, or

A^1 and A^2 or A^1 and A^3 are bonded to each other to form a ring and $-\text{A}^1-\text{A}^2-$ or $-\text{A}^1-\text{A}^3-$ are lower-alkylene or lower-alkenylene, optionally substituted by R^3 , in which one $-\text{CH}_2-$ group of $-\text{A}^1-\text{A}^2-$ or $-\text{A}^1-\text{A}^3-$ can optionally be replaced by NR^4 , S, or O,


A^5 is cycloalkyl, cycloalkyl-lower-alkyl, heterocycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkyl optionally substituted with hydroxy or lower-alkoxy, alkenyl optionally substituted with hydroxy, or alkadienyl optionally substituted with hydroxy,

R^3 is hydroxy, lower-alkoxy, thio-lower-alkoxy, $\text{N}(\text{R}^5, \text{R}^6)$, or lower-alkyl optionally substituted by hydroxy,

R^1 , R^2 , R^4 , R^5 , and R^6 independently from each other are hydrogen or lower-alkyl;


which process comprises:

a) reacting a compound of formula (II)




with a compound $(A^1, A^2, U)N-C(A^3, A^4)-L-M$, wherein V is O, S or NR^1 , M is mesylate, tosylate, triflate, Cl, Br or I, and U, A^1 , A^2 , A^3 , A^4 , A^5 , L, W, X, m, n and R^1 are as defined above, or wherein HV is mesylate, tosylate, triflate, Cl, Br or I, and M is OH, SH or NHR^1 , and R^1 is as defined above,

or b) reacting a compound of formula (III)




with a compound NHA^1, A^2 , wherein M is mesylate, tosylate, triflate, Cl, Br or I, and A^1 , A^2 , A^3 , A^4 , A^5 , L, V, W, X, m and n are as defined above,

or c) reacting a compound of formula (IV)




with a compound $(A^1, A^2, U)N-C(A^3, A^4)-L-C\equiv CH$, wherein M is Br or F_3CO_2SO , and U, A^1 , A^2 , A^3 , A^4 , A^5 , L, W, X and m are as defined above,

or d) reacting a compound of formula (V)



with a compound $(A^1, A^2, U)N-C(A^3, A^4)-L-M$, wherein M is mesylate, tosylate, triflate, Cl, Br or I, and A^1 , A^2 , A^3 , A^4 , A^5 , W, U, L, X, m and n are as defined above,

or e) hydrogenating a compound of formula (VI)



wherein V is $\text{-C}\equiv\text{C-}$, and $\text{A}^1, \text{A}^2, \text{A}^3, \text{A}^4, \text{A}^5, \text{U}, \text{W}, \text{L}, \text{X}, \text{m}$ and n are as defined above.

29. A pharmaceutical composition comprising a compound according to claim 1 and at least one of a pharmaceutically acceptable carrier or pharmaceutically acceptable adjuvant.

30. A method for the treatment and/or prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, which method comprises administering a compound according to claim 1 to a human being or animal.